|
Peter Tolias, Ph.D.
Titles:
- Executive Director, Institute
of Genomic Medicine
- Professor of Pediatrics,
UMDNJ-New Jersey Medical School
- Adjunct Professor of Molecular
Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson
Medical School

Background:
Dr. Tolias obtained his Ph.D.
from McGill University in Canada , was a post-doctoral fellow at
Harvard University and received Executive training at the Wharton
Business School of University of Pennsylvania . He has previously
served as Vice President of Worldwide Advanced Research, at Ortho-Clinical
Diagnostics - a Johnson & Johnson company, one of the world's
largest clinical diagnostic product development and manufacturing
companies, where he was responsible for Technology Assessment, Discovery
Research and Clinical Development of Biomarkers that support J&J
therapeutic products. Dr. Tolias has also served as Executive Vice
President of Corporate Development at Rosetta Genomics, a public
biotechnology company focused in microRNA-based diagnostics and
therapeutics. His role was to develop Global Strategy, lead Global
Business Development and US Operations and assist the company towards
their eventually successful IPO. Earlier in his career, Dr. Tolias
was Founder and Director of the Center for Applied Genomics, an
academic R&D center now part of the Institute of Genomic Medicine
. He previously served as an Associate Professor of Microbiology
& Molecular Genetics, UMDNJ-New Jersey Medical School , an Associate
Member at the Public Health Research Institute and earlier as an
Assistant Member.
Professional Interests
and Activities:
Dr.
Tolias's research interests are rooted in translational medicine,
focused on the discovery, validation and commercial development
of biomarkers that serve the clinical diagnostic and pharmaceutical
markets. He is currently President of NeuroMark Inc., a privately-owned
molecular diagnostic company focused on neurospsychiatric disorders.
He is also the founder of several biotechnology companies, a consulting
& capital sourcing firm specializing in the biotechnology sector
and serves on multiple boards of directors/trustees
. He has authored over 40 scientific publications and received
dozens of grants, awards and honors.
|